News

We provide the latest news
from the world of economics and finance

29 April
BRIDGEBIO PHARMA Earnings Results: $BBIO Reports Quarterly Earnings

BRIDGEBIO PHARMA ($BBIO) posted quarterly earnings results on Tuesday, April 29th. The company reported earnings of -$0.88 per share, beating estimates of -$0.94 by $0.06. The company also reported revenue of $116,630,000, beating estimates of $62,676,409 by $53,953,591.

You can see Quiver Quantitative's $BBIO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.

BRIDGEBIO PHARMA Insider Trading Activity

BRIDGEBIO PHARMA insiders have traded $BBIO stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.

Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:

  • GENETIC DISORDER L.P. KKR sold 6,000,000 shares for an estimated $197,760,000
  • GLOBAL INVESTORS LP VIKING sold 3,065,616 shares for an estimated $106,989,998
  • NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 11 sales selling 883,932 shares for an estimated $31,383,439.
  • BRIAN C STEPHENSON (CFO and Treasurer) has made 0 purchases and 5 sales selling 84,804 shares for an estimated $2,992,985.
  • ANDREA ELLIS has made 0 purchases and 2 sales selling 40,000 shares for an estimated $1,371,500.
  • HANNAH VALANTINE sold 12,875 shares for an estimated $419,499

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

BRIDGEBIO PHARMA Hedge Fund Activity

We have seen 151 institutional investors add shares of BRIDGEBIO PHARMA stock to their portfolio, and 109 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

  • FARALLON CAPITAL MANAGEMENT LLC added 2,448,000 shares (+140.1%) to their portfolio in Q4 2024, for an estimated $67,173,120
  • CITADEL ADVISORS LLC removed 1,686,753 shares (-57.3%) from their portfolio in Q4 2024, for an estimated $46,284,502
  • WOODLINE PARTNERS LP added 1,261,772 shares (+132.9%) to their portfolio in Q4 2024, for an estimated $34,623,023
  • ASSENAGON ASSET MANAGEMENT S.A. added 1,096,799 shares (+4544.6%) to their portfolio in Q1 2025, for an estimated $37,916,341
  • PICTET ASSET MANAGEMENT HOLDING SA removed 995,585 shares (-35.5%) from their portfolio in Q4 2024, for an estimated $27,318,852
  • ALYESKA INVESTMENT GROUP, L.P. added 940,415 shares (+inf%) to their portfolio in Q4 2024, for an estimated $25,804,987
  • JPMORGAN CHASE & CO removed 916,902 shares (-75.4%) from their portfolio in Q4 2024, for an estimated $25,159,790

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

This article was originally published on Quiver News, read the full story.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

х
Risk warning: Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.